A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Amazon reported $17.3 billion in advertising sales for Q4 2024, an increase of 18% -- which fell short of Wall Street ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.

Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...

The European stock markets closed sharply higher in Thursday trading as The Stoxx Europe 600 rose 1.26%, Germany's DAX gained 1.52%, the FTSE 100 in London was up 1.21%, France's CAC 40 increased 1.47 ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...